| 000 | 01920 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517101547.0 | ||
| 264 | 0 | _c20170612 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1474-4457 | ||
| 024 | 7 |
_a10.1016/S1473-3099(16)30115-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchwameis, Michael | |
| 245 | 0 | 0 |
_aSafety, tolerability, and immunogenicity of a recombinant toxic shock syndrome toxin (rTSST)-1 variant vaccine: a randomised, double-blind, adjuvant-controlled, dose escalation first-in-man trial. _h[electronic resource] |
| 260 |
_bThe Lancet. Infectious diseases _c09 2016 |
||
| 300 |
_a1036-1044 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xadministration & dosage |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBacterial Toxins _xisolation & purification |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEnterotoxins _xisolation & purification |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization Schedule |
| 650 | 0 | 4 |
_aImmunization, Secondary _xmethods |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aShock, Septic _xprevention & control |
| 650 | 0 | 4 |
_aSuperantigens _xisolation & purification |
| 650 | 0 | 4 | _aVaccination |
| 650 | 0 | 4 |
_aVaccines, Synthetic _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aRoppenser, Bernhard | |
| 700 | 1 | _aFirbas, Christa | |
| 700 | 1 | _aGruener, Corina S | |
| 700 | 1 | _aModel, Nina | |
| 700 | 1 | _aStich, Norbert | |
| 700 | 1 | _aRoetzer, Andreas | |
| 700 | 1 | _aBuchtele, Nina | |
| 700 | 1 | _aJilma, Bernd | |
| 700 | 1 | _aEibl, Martha M | |
| 773 | 0 |
_tThe Lancet. Infectious diseases _gvol. 16 _gno. 9 _gp. 1036-1044 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S1473-3099(16)30115-3 _zAvailable from publisher's website |
| 999 |
_c26120089 _d26120089 |
||